drugset / Trial / NCT05517226
Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will assess the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous injection of cotadutide in participants with mild, moderate or severe hepatic impairment compared to participants with normal hepatic function.
Timeline
- Start
- 2022-09-06
- Primary completion
- 2023-02-27
- Completion
- 2023-02-27
Outcome
Outcome not reported
Stopped (Business): “Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is based on strategic pipeline considerations. The premature closure is not due to any newly observed safety signals or a change in the risk/benefit profile.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cotadutide | Peptide | 50 ug | Subcutaneous |
Indications
No indication recorded.